Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Healthcare-Focused Investor Sees Valeant’s Value at $50; Smart Money Mixed on Stock

Page 1 of 2

As a volatile, but rather profitable sector, healthcare is the focus of many investors. Michael Castor, who manages the portfolio of Sio Capital, is focusing entirely on healthcare stocks, and as he said in his last investor letter, Sio lost around 3.3% in September amid a decline of the biotech stocks. However, in a recent video, Castor said that October was much better in terms of performance with healthcare stocks rallying by around 8%. Castor focused his attention on a particular company that had a major effect on the performance of the healthcare sector in October, Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Best Paying Jobs for Women in America

Castor has been following Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for a long time and considers that given the current environment, the stock should be trading at a fair value between $50 to $75 per share (it is currently trading at around $82, losing over 63% in the last three months). The investor that Valeant’s acquisition spree is a good solution to increase revenue and income in the short-term, but since the company makes acquisitions and slashes the infrastructure of the acquired entities, over the long-term the sales decline amid a lower spending on marketing. Valeant has been able to hide these declines by more acquisitions, but over the long-term, this strategy is unsustainable.

“We have taken the mindset that it would be reasonable to apply a higher-than-average operating margin to Valeant’s products given the culture of tremendous cost containment. It would be appropriate to continue to model that Valeant has an extremely low tax rate […] and with that we believe that fair value of Valeant is somewhere in the range of $50 to $75. That partially reflects the very substantial debt load that the company has currently,” Castor said.

Sio Capital does not own any shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and only considered going short, but missed the opportunity as the stock tanked on the back of concerns regarding the company’s practices. On the other hand, in his last investor letter, Castor provided his opinion on several other companies, including some of his high-conviction picks (see details here).

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!

Michael Castor is one of the some 730 investors that we follow as part of our small-cap strategy. Our approach allows us to identify the 15 most popular stocks among these investors, which helped us generate returns of some 102% since August 2012 (read more details here). Additionally, we monitor these investors in real-time and analyze the moves they make as well as keep an eye on their public opinion on different companies. With this in mind, let’s take a look at the recent comments made involving Valeant Pharmaceuticals Intl Inc (NYSE:VRX).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!